Article
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.
Leukemia research - 1 Nov 2011
Soverini Simona, Gnani Alessandra, De Benedittis Caterina, Castagnetti Fausto, Gugliotta Gabriele, Iacobucci Ilaria, Palandri Francesca, Rosti Gianantonio, Testoni Nicoletta, Luatti Simona, Marzocchi Giulia, Baccarani Michele, Martinelli Giovanni
Abstract excerpt
We investigated whether low-level Bcr-Abl kinase domain mutations can be detected in patients who have stable responses to first-line nilotinib-like it is known to happen in patients receiving imatinib. We screened for mutations twelve such patients by cloning and sequencing. Only one case was found to harbor mutations at low levels (including a T315I). However, major molecular response (MMR) was maintained and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.